A new class of pilocarpine-based eye drops offers a potential non-surgical solution for presbyopia, affecting nearly 2 billion people. While it may improve near vision, side effects like headaches and vision changes remain. Regulators mandate medical supervision, citing safety. Long-term effects remain unstudied, and adoption is cautious despite FDA approval.